The Bristol-Myers merger could depend on Wall Street's loudest whispers


Bristol-Myers Squibb (BMY), which is trying to convince its shareholders to support the $ 74-billion Celgene acquisition project (CELG), could scuttle its project by two highly influential financial advisers.

ISS and Glass Lewis, two global companies that make recommendations to institutional investors, have not yet considered the potential merger. Together, they claim a shareholder market share of about 97% and their verdict on the deal could spoil the largest pharmaceutical acquisition in history.

Unlock this item by subscribing to STAT Plus and enjoy your first 30 days for free!


Source link